Biblio

Export 378 results:
Author Title Type [ Year(Desc)]
Filters: First Letter Of Title is A  [Clear All Filters]
2010
R. C. Petersen, Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., and Weiner, M. W., “Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.”, Neurology, vol. 74, no. 3, pp. 201-9, 2010.
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A., “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
2011
T. E. Golde, Schneider, L. S., and Koo, E. H., “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
A. Suzuki, Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., and Alberini, C. M., “Astrocyte-neuron lactate transport is required for long-term memory formation.”, Cell, vol. 144, no. 5, pp. 810-23, 2011.
2013
A. Griciuc, Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. Hoon, Hyman, B. T., and Tanzi, R. E., “Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.”, Neuron, vol. 78, no. 4, pp. 631-43, 2013.
F. Piazza, Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitrini, R., Sakaguchi, H., Brioschi, M., Billo, G., Colombo, A., Lanzani, F., Piscosquito, G., Carriero, M. Rita, Giaccone, G., Tagliavini, F., Ferrarese, C., and DiFrancesco, J. C., “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
2014
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
2015
I. Arrieta-Cruz, Knight, C. M., and Gutiérrez-Juérez, R., “Acute Exposure of the Mediobasal Hypothalamus to Amyloid-β25-35 Perturbs Hepatic Glucose Metabolism.”, J Alzheimers Dis, 2015.
E. Diehl-Wiesenecker, von Armin, C. A. F., Dupuis, L., Müller, H. - P., Ludolph, A. C., and Kassubek, J., “Adipose Tissue Distribution in Patients with Alzheimer's Disease: A Whole Body MRI Case-Control Study.”, J Alzheimers Dis, 2015.
Q. - X. Li, Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A., Laughton, K. M., Pertile, K. K., Fowler, C. J., Rumble, R. L., Trounson, B. O., Taddei, K., Rainey-Smith, S. R., Laws, S. M., Robertson, J. S., Evered, L. A., Silbert, B., Ellis, K. A., Rowe, C. C., S Macaulay, L., Darby, D., Martins, R. N., Ames, D., Masters, C. L., and Collins, S., “Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.”, J Alzheimers Dis, vol. 48, no. 1, pp. 175-87, 2015.
S. - K. Herukka, Rummukainen, J., Ihalainen, J., Fraunberg, Mvon Und Zu, Koivisto, A. M., Nerg, O., Puli, L. K., Seppälä, T. T., Zetterberg, H., Pyykkö, O. T., Helisalmi, S., Tanila, H., Alafuzoff, I., Hiltunen, M., Rinne, J., Soininen, H., Jääskeläinen, J. E., and Leinonen, V., “Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.”, J Alzheimers Dis, 2015.
B. K. Binukumar, Shukla, V., Amin, N. D., Bhaskar, M., Skuntz, S., Steiner, J., Winkler, D., Pelech, S. L., and Pant, H. C., “Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.”, J Alzheimers Dis, 2015.
C. Weimar, Winkler, A., Dlugaj, M., Lehmann, N., Hennig, F., Bauer, M., Kröger, K., Kälsch, H., Mahabadi, A. - A., Dragano, N., Moebus, S., Hoffmann, B., Jöckel, K. - H., and Erbel, R., “Ankle-Brachial Index but Neither Intima Media Thickness Nor Coronary Artery Calcification is Associated With Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 47, no. 2, pp. 433-42, 2015.
X. Tang, Holland, D., Dale, A. M., and Miller, M. I., “APOE Affects the Volume and Shape of the Amygdala and the Hippocampus in Mild Cognitive Impairment and Alzheimer's Disease: Age Matters.”, J Alzheimers Dis, vol. 47, no. 3, pp. 645-60, 2015.
J. Foraker, Millard, S. P., Leong, L., Thomson, Z., Chen, S., C Keene, D., Bekris, L. M., and Yu, C. - E., “The APOE Gene is Differentially Methylated in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
H. Bielarczyk, Jankowska-Kulawy, A., Hofling, C., Ronowska, A., Gul-Hinc, S., Rossner, S., Schliebs, R., Pawelczyk, T., and Szutowicz, A., “AβPP-Transgenic 2576 Mice Mimic Cell Type-Specific Aspects of Acetyl-CoA-Linked Metabolic Deficits in Alzheimer's Disease.”, J Alzheimers Dis, 2015.
2016
A. Boehm-Cagan, Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., and Michaelson, D. M., “ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1219-1233, 2016.
Q. - F. Zhao, Wan, Y., Wang, H. - F., Sun, F. - R., Hao, X. - K., Tan, M. - S., Tan, C. - C., Zhang, D. - Q., Tan, L., and Yu, J. - T., “ABCA7 Genotypes Confer Alzheimer's Disease Risk by Modulating Amyloid-β Pathology.”, J Alzheimers Dis, vol. 52, no. 2, pp. 693-703, 2016.
Y. H. Fu, Hsiao, J. - H. T., Paxinos, G., Halliday, G. M., and Kim, W. Scott, “ABCA7 Mediates Phagocytic Clearance of Amyloid-β in the Brain.”, J Alzheimers Dis, vol. 54, no. 2, pp. 569-84, 2016.
L. Ni, Liu, R., Yin, Z., Zhao, H., Nedelska, Z., Hort, J., Zhou, F., Wu, W., Zhang, X., Li, M., Yu, H., Zhu, B., Xu, Y., and Zhang, B., “Aberrant Spontaneous Brain Activity in Patients with Mild Cognitive Impairment and concomitant Lacunar Infarction: A Resting-State Functional MRI Study.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1243-54, 2016.
J. Dukart, Sambataro, F., and Bertolino, A., “Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1143-59, 2016.
A. Tramutola, Pupo, G., Di Domenico, F., Barone, E., Arena, A., Lanzillotta, C., Broekaart, D., Blarzino, C., Head, E., D Butterfield, A., and Perluigi, M., “Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.”, J Alzheimers Dis, vol. 52, no. 1, pp. 359-71, 2016.
T. C. Durazzo, Korecka, M., Trojanowski, J. Q., Weiner, M. W., Hara, R. O. ', Ashford, J. W., and Shaw, L. M., “Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers.”, J Alzheimers Dis, vol. 54, no. 1, pp. 99-107, 2016.
E. Stogmann, Moser, D., Klug, S., Gleiss, A., Auff, E., Dal-Bianco, P., Pusswald, G., and Lehrner, J., “Activities of Daily Living and Depressive Symptoms in Patients with Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1043-50, 2016.
R. L. H. Handels, Joore, M. A., Vos, S. J. B., Aalten, P., Ramakers, I. H. G. B., Rikkert, M. Olde, Scheltens, P., Jansen, W. J., Visser, P. - J., van Berckel, B. M. N., van Domburg, P., Smid, M., Hoff, E., Hoogmoed, J., Bouwman, F., Claassen, J., Leentjens, A. F. G., Wolfs, C. A. G., Severens, J. L., and Verhey, F. R. J., “Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort.”, J Alzheimers Dis, vol. 52, no. 3, pp. 875-85, 2016.

Pages